These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 14720038)

  • 41. Attainments in atop: special aspects of allergy and IgE.
    Milgrom H
    Adv Pediatr; 2002; 49():273-97. PubMed ID: 12214775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-immunoglobulin E therapy for asthma.
    Owen CE
    Pulm Pharmacol Ther; 2002; 15(5):417-24. PubMed ID: 12406663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Omalizumab: a recombinant humanized anti-IgE antibody for allergic asthma.
    Ruffin CG; Busch BE
    Am J Health Syst Pharm; 2004 Jul; 61(14):1449-59. PubMed ID: 15332692
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
    Lowe PJ; Renard D
    Br J Clin Pharmacol; 2011 Aug; 72(2):306-20. PubMed ID: 21392073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-IgE therapy of asthma.
    Chung KF
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1157-60. PubMed ID: 12211407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
    Milgrom H; Fick RB; Su JQ; Reimann JD; Bush RK; Watrous ML; Metzger WJ
    N Engl J Med; 1999 Dec; 341(26):1966-73. PubMed ID: 10607813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Monoclonal antibody therapy for allergic asthma].
    Nishikawa M; Matsuse T
    Nihon Rinsho; 2002 Mar; 60(3):591-7. PubMed ID: 11904978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
    Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
    J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Omalizumab inhibits acceleration of FcεRI-mediated responsiveness of immature human mast cells by immunoglobulin E.
    Okayama Y; Kashiwakura J; Sasaki-Sakamoto T; Matsumoto K; Hashimoto N; Ohmori K; Kawakami T; Saito H; Ra C
    Ann Allergy Asthma Immunol; 2012 Mar; 108(3):188-94. PubMed ID: 22374203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-IgE therapy.
    Brownell J; Casale TB
    Immunol Allergy Clin North Am; 2004 Nov; 24(4):551-68, v. PubMed ID: 15474858
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
    Verbruggen K; Van Cauwenberge P; Bachert C
    Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M; Tonnel AB
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Omalizumab for treatment of allergic rhinitis.
    Vashisht P; Casale T
    Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is there a role for treatment of asthma with omalizumab?
    Milgrom H
    Arch Dis Child; 2003 Jan; 88(1):71-4. PubMed ID: 12495970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Anti-IGE therapy in asthma].
    Mehiri Ben Rhouma N; Béji M; Louzir B; Daghfous J
    Tunis Med; 2002 Oct; 80(10):575-80. PubMed ID: 12632749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of immunmodulators in allergen-specific immunotherapy.
    Kopp MV
    Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural and Physical Basis for Anti-IgE Therapy.
    Wright JD; Chu HM; Huang CH; Ma C; Chang TW; Lim C
    Sci Rep; 2015 Jun; 5():11581. PubMed ID: 26113483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-IgE therapy: clinical utility and mechanistic insights.
    Logsdon SL; Oettgen HC
    Curr Top Microbiol Immunol; 2015; 388():39-61. PubMed ID: 25553794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.